2006
DOI: 10.2337/dc06-0706
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

Abstract: OBJECTIVE -The efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, added to ongoing metformin therapy, were assessed in patients with type 2 diabetes who had inadequate glycemic control (HbA 1c [A1C] Ն7 and Յ10%) with metformin alone. RESEARCH DESIGN AND METHODS-After a screening diet/exercise run-in period, a metformin dose titration/stabilization period, and a 2-week, single-blind, placebo run-in period, 701 patients, aged 19 -78 years, with mild to moderate hyperglycemia (mean A1C 8.0%… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

61
540
3
13

Year Published

2007
2007
2021
2021

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 700 publications
(617 citation statements)
references
References 13 publications
61
540
3
13
Order By: Relevance
“…Sitagliptin is approved in both USA and the European Union and many other countries; indications include its use as monotherapy and in combination therapy with metformin, a sulphonylurea or TZD in people with type 2 diabetes. In a 24-week study, sitagliptin cotherapy led to significant reductions in both HbA1c (−0.65%) and fasting glucose levels (−1.4 mmol/L) in subjects inadequately controlled on metformin alone [117]. Weight reduction was not different in the active or placebo groups (a mean decrease of 0.6 kg compared with 0.7 for placebo) [117].…”
Section: Dpp-4mentioning
confidence: 99%
See 2 more Smart Citations
“…Sitagliptin is approved in both USA and the European Union and many other countries; indications include its use as monotherapy and in combination therapy with metformin, a sulphonylurea or TZD in people with type 2 diabetes. In a 24-week study, sitagliptin cotherapy led to significant reductions in both HbA1c (−0.65%) and fasting glucose levels (−1.4 mmol/L) in subjects inadequately controlled on metformin alone [117]. Weight reduction was not different in the active or placebo groups (a mean decrease of 0.6 kg compared with 0.7 for placebo) [117].…”
Section: Dpp-4mentioning
confidence: 99%
“…In a 24-week study, sitagliptin cotherapy led to significant reductions in both HbA1c (−0.65%) and fasting glucose levels (−1.4 mmol/L) in subjects inadequately controlled on metformin alone [117]. Weight reduction was not different in the active or placebo groups (a mean decrease of 0.6 kg compared with 0.7 for placebo) [117].…”
Section: Dpp-4mentioning
confidence: 99%
See 1 more Smart Citation
“…4 Like exenatide, sitagliptin is effective as a combination therapy with either metformin or pioglitazone. 5,6 Sitagliptin therapy for 24 weeks is associated with lowered fasting blood glucose and increased insulin sensitivity compared to placebo and less nausea and fewer hypoglycemic events than other therapies. Rodent studies indicate that improved glucose homeostasis from sitagliptin is associated with improved pancreatic beta cell function, and the human trials show increased insulin sensitivity.…”
mentioning
confidence: 99%
“…Newer therapies, however, such as gemtuzumab ozogamicin, when used in the months leading up to HCT, are now recognized to lead to SOS in up to 40% of patients. 4,5 When SOS does occur, the diagnosis can usually be made on clinical grounds, without recourse to liver biopsy. Painful hepatomegaly, jaundice and fluid retention are the hallmark features.…”
mentioning
confidence: 99%